Bone marrow biopsy related haemorrhage and low molecular weight heparin

Morley, Nicholas; Makris, Mike

doi:10.1046/j.1365-2141.2003.04648.x

Cited by 7 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the patients, in whom the haemorrhage could be regarded as serious but not life‐threatening, experienced some prolongation of hospital stay (12 h to 13 days), one requiring platelet transfusion and another one, who suffered haemorrhage plus infection, requiring surgical intervention and drainage of a retroperitoneal infected haematoma. The patient in whom a large haemorrhage into the buttock and thigh was considered to have contributed to death (case 6) had many risk factors for haemorrhage, including aspirin therapy plus a therapeutic dose of low‐molecular‐weight heparin, and has already been reported (Le Dieu, Luckit & Sundarasun, 2003; Morley & Makris, 2003). Another patient with life‐threatening haemorrhage (case 8) is worth considering in some detail.…”

Section: Resultsmentioning

confidence: 99%

Bone marrow biopsy morbidity and mortality: 2002 data

Bain

2004

Clin Lab Haematol

View full text Add to dashboard Cite

A survey of morbidity and mortality of bone marrow aspiration and trephine biopsy was carried out for the British Society of Haematology, covering the 12 months of 2002. Fifty-three centres reported 13,506 procedures, comprising 3927 aspiration biopsies and 9579 combined procedures. There were 17 adverse events including nine instances of haemorrhage, four infections and one haemorrhage complicated by infection. Two trephine biopsy needles broke during the procedure. One patient suffered considerable pain for 2 weeks. The adverse event may have contributed to death in two patients and in a third patient was life-threatening. Risk factors for adverse events were identified.

show abstract

Section: Resultsmentioning

confidence: 99%

Bone marrow biopsy morbidity and mortality: 2002 data

Bain

2004

Clin Lab Haematol

View full text Add to dashboard Cite

show abstract

“…A recent postal survey of members of the British Society for Haematology suggested that these procedures are generally safe, with adverse events being reported in only one per 1000 procedures (Bain, 2003, 2004). However, while complications are rare, they may be serious, and fatal outcomes have been reported (Le Dieu et al , 2003; Morley & Makris, 2003; Bain, 2004). The most frequently reported serious adverse event is bleeding.…”

Section: Results Of Bone Marrow Biopsy Surveymentioning

confidence: 99%

Bone marrow biopsy in thrombocytopenic or anticoagulated patients

Eikelboom

2005

Br J Haematol

View full text Add to dashboard Cite

Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. British Journal of Haematology, 127,[190][191][192][193][194] Keywords: anticoagulants, genetics of thrombosis and haemostasis, mutation analysis, risk factors, venous thrombosis.Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis: response to Gonzalez-Conejero et alIn reply to the study by Gonzalez-Conjero et al, we found their results on 218 Spanish White patients very interesting. As suggested in their article, there does indeed appear to be an ethnic bias and possible founder affect with regard to the W303X mutation in thrombosis patients. The frequency of both the Factor V Leiden mutation and the prothrombin 20210A variant also varies within White populations. The allelic frequencies for the factor V Leiden mutation in White subpopulations ranges from <1% to 8.5% (Zivelin et al, 1997) and appears to be absent or in very low frequencies in nonEuropean White people and totally absent in other ethnic groups (Rees et al, 1995). The 250 patients and 250 control subjects used in our study (Van de Water et al, 2004) were European White people of whom >90% were of northern European origin (McKinnon et al, 1997) with a strong influence from UK immigration. In our study we also identified another stop codon mutation (R67X) in three of our thrombosis patient cohort (n ¼ 250). It is unfortunate that Gonzalez-Conjero et al. did not extend their study to include the R67X mutation within the ZPI gene as well. Further studies of ZPI mutations in thrombosis patient populations are required, especially those in patients of northern European background, to evaluate the role of protein Z-dependent protease inhibitor in haemostasis and thrombosis. Paul Harper

show abstract

“…The majority of these events occurred following a combined aspirate/biopsy procedure in older individuals with a myeloproliferative disorder, platelet dysfunction or thrombocytopenia. Aspirin therapy 1 and low molecular weight heparin 2 have also been implicated in bone marrow biopsy‐related hemorrhages. Although case reports of retroperitoneal hemorrhages following a bone marrow biopsy have been described in the literature 3, 4, such events have not been reported in a pediatric population following a bone marrow aspirate.…”

mentioning

confidence: 99%